Sarepta Therapeutics Announces Second Quarter 2024 Financial ...

Net product revenues for the second quarter 2024 totaled $360.5 million , a 51% increase over the same quarter of the prior year ELEVIDYS ...

Sarepta Therapeutics to Announce Second Quarter 2024 Financial ...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 29, 2024-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for ...

Press Releases | Sarepta Therapeutics, Inc. - Investor Relations

8/7/24, Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments ; 7/31/24, Sarepta Therapeutics Announces ...

Sarepta Therapeutics Announces Second Quarter 2024 Financial ...

CAMBRIDGE, Mass., August 07, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, ...

Sarepta Therapeutics Second Quarter 2024 Earnings Call

Actual results and financial condition could materially differ from those stated or implied by these forward‐looking statements as a result of such risks and ...

Earnings | Sarepta Therapeutics, Inc. - Investor Relations

Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments · Sarepta Therapeutics Announces Second Quarter 2024 ...

Sarepta Therapeutics Announces Second Quarter 2024 Financial ...

Netproduct revenues for the second quarter 2024 totaled $360.5 million, a 51% increase over the same quarter of the prior yearELEVIDYS net product revenue ...

Sarepta Therapeutics to Announce Second Quarter 2024 Financial ...

Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results ... Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic ...

Sarepta Therapeutics to Announce Second Quarter 2024 Financial ...

CAMBRIDGE, Mass., July 29, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, ...

Sarepta Therapeutics Announces Third Quarter 2024 Financial ...

Net product revenues for the third quarter 2024 totaled $429.8 million , a 39% increase over the same quarter of the prior year – ELEVIDYS net product ...

Untitled

Investor Relations | Sarepta Therapeutics, Inc.

Recent Press Releases ; 11/6/24, Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments ; 10/31/24, Sarepta ...

Sarepta Therapeutics Reports Q2 2024 Financials and Recent ...

Sarepta plans to present comprehensive data on ELEVIDYS at the 29th Annual Congress of the World Muscle Society in October. Sarepta reported ...

Design Therapeutics Announces Second Quarter 2024 Financial ...

Cash Position and Operating Runway: Cash, cash equivalents and marketable securities were $261.0 million as of June 30, 2024, which the company expects to fund ...

SRPT Press Releases Sarepta Therapeutics - Market Chameleon

SRPT Latest Press Releases · Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments · Sarepta Therapeutics ...

Sarepta Therapeutics Announces Third Quarter 2024 Financial ...

Net product revenues for the third quarter 2024 totaled $429.8 million, a 39% increase over the same quarter of the prior year– ELEVIDYS net product revenue ...

Sarepta reveals lower Elevidys sales, but points to 'massive ...

Sarepta reported Wednesday afternoon that Elevidys sales totaled roughly $122 million between April and June, down from the previous quarter and ...

Sarepta Therapeutics Announces Second Quarter 2023 Financial ...

Following approval on June 22 , the first patient received commercially reimbursed ELEVIDYS (delandistrogene moxeparvovec-rokl), earlier today – Total ...

Ned Pagliarulo on X: "$SRPT Elevidys sales of $181M in the third ...

Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developm... – Net product revenues for the third ...

SEC Form 10-Q filed by Sarepta Therapeutics Inc. - Quantisnow

$SRPT. Financials · Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments · Sarepta Therapeutics Announces Second ...